What are the public health effects of direct-to-consumer drug advertising?
- PMID: 16563041
- PMCID: PMC1420390
- DOI: 10.1371/journal.pmed.0030145
What are the public health effects of direct-to-consumer drug advertising?
Abstract
Only two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits.
Conflict of interest statement
Comment in
-
Drowning or thirsting: the extremes of availability of medical information.PLoS Med. 2006 Mar;3(3):e165. doi: 10.1371/journal.pmed.0030165. Epub 2006 Mar 28. PLoS Med. 2006. PMID: 16563043 Free PMC article. No abstract available.
-
Merck's actions surrounding Vioxx.PLoS Med. 2006 Jun;3(6):e286; author reply e285. doi: 10.1371/journal.pmed.0030286. Epub 2006 Jun 27. PLoS Med. 2006. PMID: 16789808 Free PMC article. No abstract available.
References
-
- Beecher HK. The powerful placebo. J Am Med Assoc. 1955;159:1602–1606. - PubMed
-
- Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression. JAMA. 2002;287:1840–1847. - PubMed
-
- Voudouris NJ, Peck CL, Coleman G. Conditioned placebo response. J Pers Soc Psychol. 1985;48:47–53. - PubMed
-
- Kirsch I. Harrington A. Specifying nonspecifics: Psychological mechanisms of placebo effects. Cambridge (Massachusetts): Harvard University Press; 1997. pp. 166–186. The placebo effect.